These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1107 related articles for article (PubMed ID: 7895325)

  • 1. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B; Gérain J; Rosenkaimer F; Schmitz P
    Circ Shock; 1994 Aug; 43(4):191-7. PubMed ID: 7895325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
    J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
    J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
    Liénard D; Eggermont AM; Schraffordt Koops H; Kroon BB; Rosenkaimer F; Autier P; Lejeune FJ
    Melanoma Res; 1994 Mar; 4 Suppl 1():21-6. PubMed ID: 8038591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
    In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
    Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
    Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
    Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
    Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion for malignant melanoma.
    Alexander HR; Fraker DL; Bartlett DL
    Semin Surg Oncol; 1996; 12(6):416-28. PubMed ID: 8914206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.
    Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2006 May; 32(4):371-80. PubMed ID: 16520016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.